As of 2025-06-21, the EV/EBITDA ratio of Sarepta Therapeutics Inc (SRPT) is -88.98. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SRPT's latest enterprise value is 4,606.49 mil USD. SRPT's TTM EBITDA according to its financial statements is -51.77 mil USD. Dividing these 2 quantities gives us the above SRPT EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 10.4x - 12.5x | 11.2x |
| Forward P/E multiples | 11.1x - 31.4x | 15.7x |
| Fair Price | (7.78) - 68.10 | 11.81 |
| Upside | -138.7% - 239.1% | -41.2% |
| Date | EV/EBITDA |
| 2025-06-18 | -91.44 |
| 2025-06-17 | -94.26 |
| 2025-06-16 | -92.04 |
| 2025-06-13 | -146.42 |
| 2025-06-12 | -150.45 |
| 2025-06-11 | -152.23 |
| 2025-06-10 | -156.73 |
| 2025-06-09 | -159.01 |
| 2025-06-06 | -170.79 |
| 2025-06-05 | -157.23 |
| 2025-06-04 | -158.41 |
| 2025-06-03 | -156.02 |
| 2025-06-02 | -151.98 |
| 2025-05-30 | -151.49 |
| 2025-05-29 | -155.09 |
| 2025-05-28 | -150.17 |
| 2025-05-27 | -154.16 |
| 2025-05-23 | -152.56 |
| 2025-05-22 | -155.73 |
| 2025-05-21 | -160.23 |
| 2025-05-20 | -160.01 |
| 2025-05-19 | -152.70 |
| 2025-05-16 | -147.31 |
| 2025-05-15 | -143.17 |
| 2025-05-14 | -144.85 |
| 2025-05-13 | -146.49 |
| 2025-05-12 | -147.10 |
| 2025-05-09 | -146.74 |
| 2025-05-08 | -147.63 |
| 2025-05-07 | -148.35 |
| 2025-05-06 | -184.13 |
| 2025-05-05 | -244.46 |
| 2025-05-02 | -243.93 |
| 2025-05-01 | -241.32 |
| 2025-04-30 | -239.97 |
| 2025-04-29 | -234.44 |
| 2025-04-28 | -236.79 |
| 2025-04-25 | -232.97 |
| 2025-04-24 | -237.68 |
| 2025-04-23 | -229.59 |
| 2025-04-22 | -228.94 |
| 2025-04-21 | -214.39 |
| 2025-04-17 | -209.25 |
| 2025-04-16 | -209.78 |
| 2025-04-15 | -211.50 |
| 2025-04-14 | -212.25 |
| 2025-04-11 | -199.40 |
| 2025-04-10 | -196.83 |
| 2025-04-09 | -215.88 |
| 2025-04-08 | -193.23 |